TherapeuticsMD (TXMD) Change in Receivables (2010 - 2022)

TherapeuticsMD (TXMD) has reported Change in Receivables for 13 consecutive years, with -$13.6 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Change in Receivables fell 439.82% year-over-year to -$13.6 million; the trailing twelve-month figure through Sep 2022 stood at -$4.3 million (down 130.19% YoY), and the FY2021 full-year result was $4.3 million, down 47.39% from the prior year.
• Change in Receivables retreated to -$13.6 million in Q3 2022 per TXMD's latest filing, from $11.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $11.1 million in Q2 2022 and bottomed at -$13.6 million in Q3 2022.
• Historically, Change in Receivables has averaged $1.6 million across 5 years, with a median of $790885.0 in 2018.
• The sharpest annual moves came in 2018 and 2022: Change in Receivables sank 2767.32% in 2018, then jumped 48326.09% in 2022.
• Over 5 years, Change in Receivables stood at -$1.8 million in 2018, then soared by 629.91% to $9.3 million in 2019, then slipped by 7.4% to $8.6 million in 2020, then plunged by 114.32% to -$1.2 million in 2021, then sank by 1006.81% to -$13.6 million in 2022.
• According to Business Quant data, Change in Receivables over the past three periods registered -$13.6 million, $11.1 million, and -$489000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.